SCHEMBL90173

SCHEMBL90173

COCCCOc1cc(C)c(F)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 4/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
TDP1 Q9NUW8 1/20 0.36
RET P07949 1/20 0.34
KIF5B P33176 1/20 0.34
TSHR P16473 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 1/20 0.33
GRIN2B Q13224 1/20 0.32
USP2 O75604 1/20 0.32
MAPT P10636 1/20 0.32
HTR2A P28223 1/20 0.32
HPGD P15428 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89783 0.84 KDM4E (0.34) LMNAHTTKDM4EKMT2AL3MBTL1
SCHEMBL88784 0.83 LMNA (0.36) LMNAHTTKDM4EKMT2AL3MBTL1
SCHEMBL29467973 0.79 L3MBTL1 (0.35) LMNAHTTKDM4EKMT2AL3MBTL1
SCHEMBL2615465 0.79 PPARA (0.40) LMNAHTTKDM4ETDP1TSHR
SCHEMBL89281 0.78 ALDH1A1 (0.44) LMNAHTTKDM4EKMT2AALDH1A1
SCHEMBL22138650 0.78 MRGPRX4 (0.47) LMNAKDM4EL3MBTL1TDP1TSHR
SCHEMBL12020661 0.78 HTT (0.46) LMNAHTTKDM4EKMT2AL3MBTL1
SCHEMBL89869 0.77 BRD4 (0.33) LMNAHTTKDM4EKMT2ARET
SCHEMBL8256560 0.76 RET (0.41) KMT2AL3MBTL1TDP1RETKIF5B
SCHEMBL12180304 0.76 RET (0.41) KMT2AL3MBTL1TDP1RETKIF5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 LMNA 1594/4885HTT 943/4885KDM4E 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.